Visualitzant Institut d’Investigació Biomèdica de Girona (IdIBGi) per matèria "Antineoplastic agents"

Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin

Silibinin is a direct inhibitor of STAT3

Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers

Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation

Fatty Acid Synthase is a key enabler for endocrine resistance in Heregulin-overexpressing Luminal B-like breast cancer

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

Lung Cancer Management with Silibinin: A Historical and Translational Perspective

Silibinin suppresses tumor cell-intrinsic resistance to Nintedanib and enhances its clinical activity in Lung Cancer

Clinical management of COVID-19 in cancer patients with the STAT3 inhibitor silibinin